| COR |
Report |
Adj. Diluted EPS (Q3 FY26) |
BEAT |
pred ~$4.45 vs. cons $4.35 |
MEDIUM |
| COR |
Report |
U.S. Healthcare Solutions OI (Q3 FY26) |
BEAT |
pred ~$960M vs. cons $940M |
MEDIUM |
| COR |
Report |
Revenue (Q3 FY26) |
IN-LINE |
pred ~$84.5B vs. cons $84.4B |
MEDIUM |
| COR |
Guide |
Adj. EPS (FY2026) |
UNCHANGED |
guide ~$17.65-$17.90 maintained vs. cons $17.79 |
HIGH |
| COR |
Guide |
Revenue Growth (FY2026) |
UNCHANGED |
guide 4-6% maintained vs. cons at midpoint |
HIGH |
| COR |
Guide |
Q4 Cadence / Biosimilar Commentary |
BETTER |
stabilization language; Q4 strongest quarter reiterated |
MEDIUM |
| COR |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.8% |
— |
MEDIUM |
| COR |
Return |
5-day cumulative residual |
+2.5% (STABILIZE) |
STABILIZE — EPS beat absorbed into modest upward estimate revisions; no large revision catalyst from maintained FY guide; stock consolidates near post-print level |
MEDIUM |